Curi Capital LLC Has $46.08 Million Holdings in Eli Lilly and Company $LLY

Curi Capital LLC increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 52.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 59,115 shares of the company’s stock after purchasing an additional 20,435 shares during the quarter. Eli Lilly and Company accounts for approximately 0.9% of Curi Capital LLC’s investment portfolio, making the stock its 23rd largest position. Curi Capital LLC’s holdings in Eli Lilly and Company were worth $46,082,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Braun Bostich & Associates Inc. lifted its holdings in shares of Eli Lilly and Company by 2.5% during the 2nd quarter. Braun Bostich & Associates Inc. now owns 527 shares of the company’s stock worth $411,000 after acquiring an additional 13 shares during the period. Rise Advisors LLC raised its position in Eli Lilly and Company by 1.8% during the second quarter. Rise Advisors LLC now owns 732 shares of the company’s stock valued at $571,000 after purchasing an additional 13 shares in the last quarter. Occidental Asset Management LLC lifted its stake in Eli Lilly and Company by 0.7% during the second quarter. Occidental Asset Management LLC now owns 1,966 shares of the company’s stock worth $1,533,000 after purchasing an additional 13 shares during the last quarter. New Insight Wealth Advisors boosted its holdings in shares of Eli Lilly and Company by 3.4% in the 2nd quarter. New Insight Wealth Advisors now owns 394 shares of the company’s stock valued at $307,000 after purchasing an additional 13 shares in the last quarter. Finally, Dash Acquisitions Inc. boosted its holdings in shares of Eli Lilly and Company by 2.8% in the 2nd quarter. Dash Acquisitions Inc. now owns 485 shares of the company’s stock valued at $387,000 after purchasing an additional 13 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently commented on LLY shares. Loop Capital set a $950.00 price target on Eli Lilly and Company in a report on Monday, November 10th. Daiwa Capital Markets boosted their target price on Eli Lilly and Company from $700.00 to $940.00 in a research note on Monday, November 10th. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Leerink Partnrs raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Monday, November 10th. Finally, CICC Research increased their price objective on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a research note on Thursday, November 13th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $1,109.24.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,027.68 on Friday. The business has a 50 day moving average of $939.47 and a 200-day moving average of $818.98. The company has a market capitalization of $971.55 billion, a P/E ratio of 50.28, a P/E/G ratio of 1.12 and a beta of 0.37. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,111.99. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same period last year, the company earned $1.18 EPS. The firm’s revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a $1.73 dividend. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is presently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.